Litcius/Paper detail

Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study

Maria Luisa Brandi, Suzanne M. Jan de Beur, Karine Briot, Thomas O. Carpenter, Hae Il Cheong, Martine Cohen‐Solal, Rachel Crowley, Richard Eastell, Yasuo Imanishi, Erik A. Imel, Steven Ing, Karl Insogna, Nobuaki Ito, M K Javaid, Peter Kamenický, Richard Keen, Takuo Kubota, Robin Lachmann, Farzana Perwad, Pisit Pitukcheewanont, Anthony A. Portale, Stuart H. Ralston, Hiroyuki Tanaka, Thomas J. Weber, Han‐Wook Yoo, Wei Sun, Angela Williams, Annabel Nixon, Yasuhiro Takeuchi

2022Calcified Tissue International24 citationsDOI

Topics & Concepts

PlaceboSubgroup analysisPost-hoc analysisClinical endpointMedicineHypophosphatemiaInternal medicineBrief Pain InventoryWOMACPhysical therapyConfidence intervalRandomized controlled trialChronic painOsteoarthritisPathologyAlternative medicineParathyroid Disorders and TreatmentsMagnesium in Health and DiseaseTherapeutic Uses of Natural Elements
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study | Litcius